F-star CEO tells Scrip reconfiguring biotech’s pact with Merck KGaA on oncology asset FS118 is UK group’s first big move towards a wholly owned portfolio strategy.
A revision to F-star’s agreement with Merck KGaA has propelled the UK-based bispecific antibody specialist on a new course to develop a proprietary pipeline, its CEO said.
The 2017 immuno-oncology R&D collaboration with Merck KGaA granted the German group exclusive development and commercial rights to five novel bispecific antibodies, including FS118, a first-in-class antagonist inducing dual blockade...
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
One Phase III trial hits but a second study misses by a mile.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback
